BioXell Announces New Members of Management Team
BioXell S.p.A. announced that Niels Ackermann will be joining the Company as Chief Financial Officer as of April 16, 2007, and that Bertrand Lehuu has joined the Company as Chief Business Officer since March 1, 2007. Alex Martin, who has held the positions of CBO and, currently, CFO, will be returning to the United States for personal reasons.
Mr. Ackermann began his career in the investment banking division of Goldman Sachs. He subsequently joined Cardion AG as CFO, and later became CFO of Wilex AG. He joins BioXell from Morgan Stanley in London where he was a Vice President in the firm's Global Capital Markets division, advising and covering corporate clients in the German-speaking region on equity-related financing structures, including IPOs and other equity capital measures.
Mr. Lehuu has 25 years of pharmaceutical industry experience acquired in big pharma and biotech, including 15 years of international business and corporate development expertise. He served as Global Licensing Director at the headquarters of F. Hoffmann-La Roche Ltd in Basel, Switzerland and subsequently as Senior Executive Licensing at the Roche spin-off Basilea Pharmaceutica Ltd. Mr. Lehuu later became VP Business Development at Flamel Technologies and more recently VP Business Development at the private CNS company Neuro3d SA based in France.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.